Introducing Our Lead Product, YuuthTM – Rebooting the Genetic Program to Restore Youthful Beauty
Ponce Therapeutics is using advanced technologies to develop novel therapeutics targeting the fundamental mechanisms of aging. Its lead programs utilize proprietary, state-of-the-art biotechnology platforms to restore the youthful balance of aged or “senescent” and young cells in the skin, targeting ApoptiCIDeTM, our proprietary cell elimination technology, to the senescent cells for their removal. This provides a “reboot” of one’s genetic program to turn the clock on one’s skin back to its youthful exuberance.
Proprietary Platform
Targeting Senescent Cells for Elimination
Elimination of pro-inflammatory senescent cells has been shown to suppress cancer and rejuvenate tissues by restoring stem cell niches to their healthy state.
Clinical Pipeline
Development of our lead program targeting in situ carcinoma of the skin
PONCE’s lead program delivers p16-targeted ApoptiCIDeTM to keratinocytes for the treatment of Bowen’s lesions using our proprietary delivery technology.
Ponce Therapeutics Executes Worldwide Exclusive License to Speratum Biopharma’s Nano-in™ and No-Pass Mimic™ Nanoparticle Technologies in Anti-Aging and Other Products Initially for Skin
Ponce Therapeutic's ("Ponce") lead product, ReBeaut™, is a microneedle patch containing nanoparticles carrying its proprietary ApoptiCIDe™ cell elimination gene therapy technology targeting senescent keratinocytes and fibroblasts in the skin Speratum Biopharma ("Speratum")…
Read More